Company news

AbbVie Inc. news in 2026

AbbVie Inc.'s news releases, calls and decks from 2026, newest first.

View company

Mission BioCapital Announces Opening of $4 Million 2026 Platinum Program Contest and 2025 Platinum Ticket Investments

April 2, 2026

Correction: AbbVie

March 31, 2026

AbbVie to Host First-Quarter 2026 Earnings Conference Call

March 31, 2026

Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 American Academy of Dermatology Meeting (AAD)

March 30, 2026

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

March 27, 2026

Allergan Aesthetics Reinforces Scientific Differentiation and Leadership with 21 Evidence-Based E-Posters at the 2026 Aesthetic & Anti-Aging Medicine World Congress (AMWC)

March 26, 2026

Allergan Aesthetics Ushers in a New Age of Hyaluronic Acid (HA) Injectables with JUVÉDERM® at AMWC Monaco

March 26, 2026

Global Botulinum Toxin Market Outlook: AbbVie (Allergan), Ipsen & Revance Lead Aesthetic Growth Across North America

March 25, 2026

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

March 24, 2026

Breckenridge announces launch of Milnacipran HCl Tablets, generic equivalent of Savella®

March 19, 2026

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

March 19, 2026

Alloy Therapeutics Enters Into Agreement to Advance Novel Antibody Discovery Platform

March 17, 2026

Allergan Aesthetics Redefines Skin Quality Communication with Launch of Skin Quality Index

March 16, 2026

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

March 9, 2026

Allergan Aesthetics highlights medical weight loss (MWL) data and the changing profile of patients

March 4, 2026

AbbVie to Present at the Leerink Partners Global Healthcare Conference

March 3, 2026

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

March 2, 2026

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

February 24, 2026

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

February 23, 2026

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

February 20, 2026

AbbVie Declares Quarterly Dividend

February 19, 2026

Facial Injectable Analysis Report 2025: An $18.89 Billion Market by 2029, Driven by New Product Launches, Emerging Markets, AI Innovations, Male Aesthetics, Younger Demographics

February 17, 2026

AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

February 4, 2026

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo

February 3, 2026

AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships

January 29, 2026

Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine

January 28, 2026

Biocom Announces Powerhouse Keynote Panel Featuring Heads of Discovery and Research & Development from AbbVie, Amgen and Eli Lilly at 2026 Global Partnering & Investor Conference

January 21, 2026

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

January 16, 2026

AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans

January 12, 2026

AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors

January 12, 2026

AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

January 7, 2026

MAVIRET® receives Health Canada Approval for the Treatment of Acute Hepatitis C Virus

January 6, 2026

AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 5, 2026

← Newer news releases

Calls in 2026

Decks in 2026